Hematology billing
Every other cost-sharing obligation in Medicare is a sum of money. The blood deductible is a quantity of blood: three units of whole blood or packed red cells per calendar year, which the beneficiary may satisfy either by paying the provider's charge or by having the blood replaced. It applies to red cells and whole blood and to nothing else in the blood bank, and it does not touch the charges for processing, storing or administering any of it.
- The deductible is the first three units of whole blood or packed red cells in a calendar year
- A unit of packed red cells is treated as the equivalent of a unit of whole blood
- The obligation can be discharged by replacement rather than by payment
- It does not apply to platelets, plasma, gamma globulin or albumin, nor to processing and administration charges
This is an educational guide to how billing works for hematology — its workflow, coding, and payer considerations. It is general information, not a statement that US Medical Billing serves this specialty, and not billing, coding, or legal advice.
What makes hematology billing distinct
The blood deductible is the specialty's defining oddity, and it is genuinely unlike anything else in the program. Under 42 CFR 409.87 and 42 CFR 410.161, Medicare does not pay for the first three units of whole blood or units of packed red cells a beneficiary receives in a calendar year, and a unit of packed red cells is treated as the equivalent of a unit of whole blood. It is in addition to the ordinary Part A and Part B deductibles rather than part of them, and it is shared across the two: the Part A blood deductible is reduced to the extent the Part B one has been applied, and the reverse. A beneficiary who received one unit as an outpatient and later three as an inpatient has Medicare paying for the third of the later units.
The beneficiary's obligation can be met without money. The regulation gives the beneficiary the option of paying the provider's charges for the blood or arranging for it to be replaced. Replacement is not a courtesy: a blood replacement offer made by the beneficiary, or by an individual or a blood bank on their behalf, discharges the obligation where the replacement blood meets the criteria in the Food and Drug Administration's regulations -- that it would not endanger the health of the beneficiary, and that the prospective donor's health would not be endangered by making the donation. And the regulation goes further than an accepted offer: a provider is precluded from charging even where it or its blood supplier rejects the replacement offer. An offer that never became a donation still cancels the charge.
There is a further exception that removes the obligation entirely. Where the provider obtained the blood at no charge other than a processing or service charge, the beneficiary is not responsible for those units at all, because the blood is deemed to have been replaced. Since a great deal of the supply reaches hospitals exactly that way, the deductible that looks formidable on paper is often already satisfied before anyone asks the patient about it -- which is precisely why a practice needs to know which of its units arrived on which footing before it bills a beneficiary for any of them.
The boundary of the deductible is drawn around the product, not around the transfusion. It does not apply to other blood components such as platelets, fibrinogen, plasma, gamma globulin and serum albumin, and it does not apply to the costs of processing, storing and administering blood. A hematology service transfusing platelets into a thrombocytopenic patient is delivering a product outside the deductible while the same patient's red cells are inside it, and the transfusion service itself is outside it in both cases. Two lines on one encounter, on two different cost-sharing footings.
This page is about non-malignant hematology and transfusion practice. Where a hematology-oncology practice administers separately payable Part B drugs from single-dose containers, the governing rules are the discarded-drug attestation and the administration hierarchy, which are the subject of the separate oncology guide under Solutions rather than of this page. What belongs here instead is the other product with a payment structure of its own: clotting factor, for which section 1842(o)(5)(C) of the Social Security Act requires a separately payable furnishing fee for the items and services associated with supplying it -- a fee for the act of furnishing, updated each calendar year by the change in the consumer price index for medical care, and payable in addition to the inpatient prospective payment amount for a hemophilia inpatient rather than absorbed into it.
How hematology billing flows
A transfusion encounter produces several lines that answer to different rules, and the deductible attaches to only one of them.
Establishing what the patient has already received
The deductible runs by calendar year and across Part A and Part B together, so the count that matters is units received anywhere in the program this year -- not units received at this facility, and not units on this claim.
Common operational challenges
The recurring difficulty is that the facts deciding cost-sharing are held by the blood bank rather than by the billing system.
A running total nobody owns
The three-unit count is per beneficiary per calendar year across both parts of the program, so no single provider's records hold it. Billing a patient for deductible units without knowing what they received elsewhere risks charging for units already satisfied.
A cost-share that can be paid in kind
Replacement is a route most patient-financial-services workflows have no field for. Explaining it, recording an offer, and knowing that a rejected offer still cancels the charge are all outside the normal collections script.
Supply provenance as a billing fact
Whether a unit came to the provider at no charge beyond a processing or service charge decides whether the patient owes anything for it. That is a fact created in procurement and needed at the statement.
Components on one encounter, rules on two
A patient receiving red cells and platelets in one session is receiving one product inside the deductible and one outside it, with the transfusion service outside it for both. A single patient-responsibility figure for the encounter will be wrong.
Documentation and coding considerations
The notes below describe cost-sharing and payment rules from the Medicare regulations and manuals; they do not reproduce any code descriptions.
What the deductible covers, and how units are counted
Medicare does not pay for the first three units of whole blood or units of packed red cells furnished in a calendar year, with a unit of packed red cells treated as the equivalent of a unit of whole blood. It is additional to the Part A inpatient deductible and coinsurance and to the Part B annual deductible.
What it does not cover
The deductible does not apply to other blood components such as platelets, fibrinogen, plasma, gamma globulin and serum albumin, and it does not apply to the costs of processing, storing and administering blood. Those charges follow ordinary cost-sharing.
Replacement, and the offer that suffices
The beneficiary may pay the provider's charges or arrange replacement. An offer from the beneficiary, another individual or a blood bank discharges the obligation where the blood meets the criteria in 21 CFR part 640, and the provider may not charge even where it or its blood supplier rejects the offer.
Blood deemed replaced
Where the provider obtained the blood or red cells at no charge other than a processing or service charge, the beneficiary is not responsible for those units, because the blood is deemed to have been replaced.
The clotting factor furnishing fee
Section 1842(o)(5)(C) of the Act requires a furnishing fee for items and services associated with clotting factor, separately payable to entities that furnish it unless those costs are paid through another payment system, and updated each calendar year by the change in the consumer price index for medical care. For a hemophilia inpatient in a prospective-payment hospital it is paid in addition to the inpatient payment.
Denial and rejection risks
Two of these are billing a patient for something they do not owe, which is a worse failure than a denial.
Charging for units that were deemed replaced
Where blood was obtained at no charge beyond a processing or service charge, or where a qualifying replacement offer was made, the provider may not charge the beneficiary. A statement issued anyway is a collection of money that was never owed.
Applying the deductible to the wrong component
Platelets, plasma, fibrinogen, gamma globulin and albumin are outside it. Applying a blood deductible to them overstates patient responsibility on exactly the products a hematology service transfuses most often.
Applying it to the service rather than the product
Processing, storage and administration are outside the deductible. Treating the whole transfusion encounter as deductible blood misstates both the Medicare payment and the patient balance.
A count that ignores the other part of the program
Because the Part A and Part B blood deductibles reduce each other, units counted only within one setting produce the wrong remaining liability -- in either direction.
Apheresis outside the covered indications or settings
The national determination lists the covered indications, qualifies several as last-resort or conditional on failure of conventional therapy, and limits the settings to a hospital or a clinic meeting stated physician-presence and supervision conditions.
Payer-process considerations
This is one of the few places where a federal cost-sharing rule assumes a physical supply chain.
A deductible that crosses Part A and Part B
The two blood deductibles reduce one another, so a beneficiary's liability is a single running total across settings. The regulation's own worked example follows a beneficiary from an outpatient unit into an inpatient stay.
Replacement criteria set by another agency
Whether a replacement offer discharges the obligation depends on Food and Drug Administration donor and blood regulations rather than on Medicare policy -- so the test is about donor and recipient safety, not about billing.
A furnishing fee outside the usual bundles
Clotting factor's furnishing fee survives the inpatient prospective payment for a hemophilia inpatient rather than being folded into it, and is separately payable elsewhere unless those costs are already paid through another payment system.
Commercial plans and Medicare Advantage differ
The blood deductible described here is Original Medicare's. Commercial plans and Medicare Advantage plans set their own cost-sharing for blood products and generally do not offer a replacement route, so the patient conversation is different for the same transfusion.
Revenue-cycle checkpoints
The first four all have to happen before a patient statement, not after one.
- Establish how many deductible units the beneficiary has already received this calendar year, across Part A and Part B
- Identify the component before applying any cost-sharing, since only whole blood and packed red cells are inside the deductible
- Confirm whether the units were obtained at no charge beyond a processing or service charge, which deems them replaced
- Record any replacement offer, including one that was rejected, because a qualifying offer bars the charge either way
- Split processing, storage and administration charges from the product line so the deductible lands on the right amount
- Bill the clotting factor furnishing fee separately where the costs are not already paid through another payment system
- Check apheresis against the determination's indication list and its setting and supervision conditions before scheduling
- Review patient statements for blood charges the regulation prohibits, rather than waiting for a beneficiary to query one
Related & connected
Services, tools, background reading and definitions that connect to the hematology revenue-cycle steps above.
Related services
- Patient billing & supportA cost-share that can be paid in blood rather than money, and that is often not owed at all.
- Coding supportSeparating product from processing, storage and administration on a transfusion claim.
- Payment postingPosting a claim where one deductible ran alongside two others and reduced across parts.
Calculators & tools
- Patient cost estimatorEstimating a balance before service, on an encounter where part of it may not be owed.
- HCPCS code lookupThe Level II code set that carries blood products, clotting factors and their units.
- Medicare claim readiness checklistWhat has to be established before a Medicare claim and its patient balance are released.
From the Knowledge Base
- Patient responsibilityHow a patient balance is derived -- and here, one that can be discharged without money.
- How Medicare is structuredWhy a deductible that reduces across Part A and Part B needs both sides counted together.
- Collecting at time of serviceThe desk conversation this deductible complicates, because the amount may already be satisfied.
- Medicare Part B drugs and biologicalsThe framework clotting factors and other biologicals are priced and billed within.
Glossary
- DeductibleThe concept this benefit expresses in units of a physical product rather than in money.
- Cost sharingThe category a blood deductible belongs to, sitting on top of the ordinary ones.
- Patient responsibilityWhat a beneficiary owes for the first units -- unless the blood was replaced or deemed replaced.
- MS-DRGThe inpatient payment group a clotting factor furnishing fee is paid in addition to.
Frequently asked questions
What is the Medicare blood deductible?
A cost-sharing obligation measured in units rather than dollars. Under 42 CFR 409.87 and 42 CFR 410.161, Medicare does not pay for the first three units of whole blood or units of packed red cells a beneficiary receives in a calendar year, with a unit of packed red cells treated as the equivalent of a unit of whole blood. It sits on top of the ordinary Part A and Part B deductibles rather than inside them. The Part A and Part B blood deductibles also reduce one another, so a beneficiary who received one unit under Part B and then three under Part A has Medicare paying for the third of the later units.
Can a patient satisfy it without paying?
Yes. The regulation gives the beneficiary the option of paying the provider's charges for the blood or arranging for it to be replaced. A replacement offer made by the beneficiary, or by another individual or a blood bank on their behalf, discharges the obligation where the replacement blood meets the criteria in the Food and Drug Administration's regulations at 21 CFR part 640 -- that it would not endanger the beneficiary's health and that the prospective donor's health would not be endangered by donating. The regulation then adds a striking rule: the provider is precluded from charging even if it or its blood supplier rejects the replacement offer. The offer itself, not the donation, ends the charge.
When is the patient not responsible at all?
Where the provider obtained the blood or packed red cells at no charge other than a processing or service charge. In that case the regulation deems the blood to have been replaced, and the beneficiary is not responsible for those units. Because a significant share of hospital supply arrives on exactly that footing, the practical question in a billing office is usually not how to collect the deductible but whether it is owed at all -- which depends on how each unit was obtained.
Does the deductible apply to platelets and plasma?
No. Both regulations state that the deductible does not apply to other blood components such as platelets, fibrinogen, plasma, gamma globulin and serum albumin, and does not apply to the costs of processing, storing and administering blood. So one transfusion session can produce a red cell line inside the deductible, a platelet line outside it, and administration and processing charges outside it as well. A single patient-responsibility figure calculated across the encounter will not be right.
What is the clotting factor furnishing fee?
A payment for the act of supplying the product, separate from the product itself. Section 303(e)(1) of the Medicare Modernization Act added section 1842(o)(5)(C) of the Social Security Act, which requires a furnishing fee for items and services associated with clotting factor. The Claims Processing Manual states that it is separately payable to entities that furnish clotting factor unless the associated costs are paid through another payment system, and that it is updated each calendar year by the percentage increase in the consumer price index for medical care. For a hemophilia inpatient in a prospective-payment hospital, clotting factor and the furnishing fee are paid in addition to the inpatient payment rather than absorbed into it.
Sources
Last reviewed August 1, 2026.
- Office of the Federal Register / eCFR42 CFR 409.87 Blood deductible -- the first three units of whole blood or packed red cells in a calendar year, the equivalence of a unit of packed red cells to a unit of whole blood, the exclusion of other blood components and of processing, storage and administration costs, the reduction against the Part B blood deductible with a worked example, the beneficiary's option to pay or arrange replacement, the deeming of blood obtained at no charge beyond a processing or service charge, the bar on charging where a replacement offer is made even if rejected, and the criteria for a valid replacement offer under 21 CFR part 640
- Office of the Federal Register / eCFR42 CFR 410.161 Part B blood deductible -- the same three-unit structure under Part B, its reduction to the extent a blood deductible has been applied under Part A, its addition to the Part B annual deductible, and the supplier's right to charge the beneficiary the reasonable charge for the first three units only to the extent those units are not replaced
- Centers for Medicare & Medicaid Services (CMS)Medicare Claims Processing Manual (Pub. 100-04), Chapter 17 §§80.4 and 80.4.1 -- billing for hemophilia clotting factors, their payment in addition to the inpatient prospective payment for a hemophilia inpatient, and the clotting factor furnishing fee required by section 1842(o)(5)(C) of the Social Security Act, separately payable unless the associated costs are paid through another payment system and updated annually by the consumer price index for medical care
- Centers for Medicare & Medicaid Services (CMS)Medicare National Coverage Determinations Manual (Pub. 100-03) §110.14 Apheresis (Therapeutic Pheresis) -- the definition of apheresis as an autologous procedure for Medicare coverage purposes, the list of covered indications including those qualified as last resort or as requiring failure of conventional therapy, and the setting conditions requiring a hospital or a clinic meeting stated physician-presence and supervision requirements
Ready to improve your revenue cycle?
Tell us about your practice and we’ll tell you where we would start.